Maayan Konigstein1, Mahesh V Madhavan2, Ori Ben-Yehuda3, Hussein M Rahim2, Iva Srdanovic1, Fotis Gkargkoulas1, Ghazaleh Mehdipoor1, Evan Shlofmitz3, Akiko Maehara3, Björn Redfors4, Ankita K Gore2, Thomas McAndrew1, Gregg W Stone3, Ziad A Ali5. 1. Clinical Trials Center, Cardiovascular Research Foundation, New York, NY. 2. Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY. 3. Clinical Trials Center, Cardiovascular Research Foundation, New York, NY; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY. 4. Clinical Trials Center, Cardiovascular Research Foundation, New York, NY; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. 5. Clinical Trials Center, Cardiovascular Research Foundation, New York, NY; Division of Cardiology, NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY. Electronic address: zaa2112@columbia.edu.
Abstract
BACKGROUND:Drug-eluting stents (DESs) have improved clinical outcomes of patients undergoing percutaneous coronary intervention (PCI). Nevertheless, adverse events related to previously treated lesion still occur. We sought to evaluate the incidence and predictors of target lesion failure (TLF) in patients undergoing contemporary DES implantation. METHODS: Patient-level data from 6 prospective, randomized trials were pooled, and DES treatment outcomes were analyzed at up to 5 years. Primary outcome was TLF (cardiac death, target lesion revascularization, or target vessel myocardial infarction). Cox proportional-hazards model was used to identify predictors of TLF. RESULTS: Overall, 10,072 patients were included in the analysis. TLF rate was 1.7%, 4.3%, and 11.9% at 30 days, 1 year, and 5 years, respectively. The only independent predictor of TLF at 30 days was stent length (hazard ratio [HR] 1.017, 95% CI 1.011-1.024, P < .0001). Moderate/severe calcification, stent length and post procedural diameter sthenosis were predictors between 30 days to 1 year but not at 1 to 5 years. Reference vessel diameter was the only lesion-related predictor at 5 years (P = .003). Clinical predictors of TLF between 30 days and 1 year were diabetes and hypertension (P < .01 for both), and between 1 and 5 years, diabetes (HR 1.40, 95% CI 1.13-1.73, P = .002), prior coronary artery bypass grafting (HR 2.52, 95% CI 1.92-3.30, P < .0001), and prior PCI (HR 1.29, 95% CI 1.02-1.64, P = .04) predicted TLF. CONCLUSIONS: Predictors of TLF vary in the early, late, and very late postprocedural periods. Reference vessel diameter was the only lesion-related predictor of long-term TLF; clinical predictors were diabetes, prior coronary artery bypass grafting, and prior PCI.
RCT Entities:
BACKGROUND: Drug-eluting stents (DESs) have improved clinical outcomes of patients undergoing percutaneous coronary intervention (PCI). Nevertheless, adverse events related to previously treated lesion still occur. We sought to evaluate the incidence and predictors of target lesion failure (TLF) in patients undergoing contemporary DES implantation. METHODS:Patient-level data from 6 prospective, randomized trials were pooled, and DES treatment outcomes were analyzed at up to 5 years. Primary outcome was TLF (cardiac death, target lesion revascularization, or target vessel myocardial infarction). Cox proportional-hazards model was used to identify predictors of TLF. RESULTS: Overall, 10,072 patients were included in the analysis. TLF rate was 1.7%, 4.3%, and 11.9% at 30 days, 1 year, and 5 years, respectively. The only independent predictor of TLF at 30 days was stent length (hazard ratio [HR] 1.017, 95% CI 1.011-1.024, P < .0001). Moderate/severe calcification, stent length and post procedural diameter sthenosis were predictors between 30 days to 1 year but not at 1 to 5 years. Reference vessel diameter was the only lesion-related predictor at 5 years (P = .003). Clinical predictors of TLF between 30 days and 1 year were diabetes and hypertension (P < .01 for both), and between 1 and 5 years, diabetes (HR 1.40, 95% CI 1.13-1.73, P = .002), prior coronary artery bypass grafting (HR 2.52, 95% CI 1.92-3.30, P < .0001), and prior PCI (HR 1.29, 95% CI 1.02-1.64, P = .04) predicted TLF. CONCLUSIONS: Predictors of TLF vary in the early, late, and very late postprocedural periods. Reference vessel diameter was the only lesion-related predictor of long-term TLF; clinical predictors were diabetes, prior coronary artery bypass grafting, and prior PCI.
Authors: Joshua M Stolker; Kevin F Kennedy; Jason B Lindsey; Steven P Marso; Michael J Pencina; Donald E Cutlip; Laura Mauri; Neal S Kleiman; David J Cohen Journal: Circ Cardiovasc Interv Date: 2010-07-06 Impact factor: 6.546
Authors: Donald E Cutlip; Stephan Windecker; Roxana Mehran; Ashley Boam; David J Cohen; Gerrit-Anne van Es; P Gabriel Steg; Marie-angèle Morel; Laura Mauri; Pascal Vranckx; Eugene McFadden; Alexandra Lansky; Martial Hamon; Mitchell W Krucoff; Patrick W Serruys Journal: Circulation Date: 2007-05-01 Impact factor: 29.690
Authors: Emmanouil S Brilakis; Christopher Lichtenwalter; Abdul-rahman R Abdel-karim; James A de Lemos; Owen Obel; Tayo Addo; Michele Roesle; Donald Haagen; Bavana V Rangan; Bilal Saeed; Joseph K Bissett; Rajesh Sachdeva; Vassilios V Voudris; Panagiotis Karyofillis; Biswajit Kar; James Rossen; Panayotis Fasseas; Peter Berger; Subhash Banerjee Journal: JACC Cardiovasc Interv Date: 2011-02 Impact factor: 11.195
Authors: Cosmo Godino; Carlo Andrea Pivato; Mauro Chiarito; Michael Donahue; Luca Testa; Riccardo Colantonio; Alberto Cappelletti; Diego Milazzo; Rosario Parisi; Annamaria Nicolino; Shahram Moshiri; Gianfranco Aprigliano; Altin Palloshi; Dennis Zavalloni Parenti; David Rutigliano; Nicola Locuratolo; Francesco Melillo; Andrea Scotti; Luca Arrigoni; Matteo Montorfano; Rossella Fattori; Patrizia Presbitero; Gennaro Sardella; Francesco Bedogni; Alberto Margonato; Carlo Briguori; Antonio Colombo Journal: Int J Cardiol Date: 2017-10-15 Impact factor: 4.164
Authors: Hazem Al Muradi; Aditya Mehra; Joseph Okolo; Helen Vlachos; Faith Selzer; Oscar C Marroquin; Kimberly Skelding; Elizabeth M Holper; David O Williams; J Dawn Abbott Journal: Cardiovasc Revasc Med Date: 2012 Nov-Dec
Authors: Martin B Leon; Laura Mauri; Jeffrey J Popma; Donald E Cutlip; Eugenia Nikolsky; Charles O'Shaughnessy; Paul A Overlie; Brent T McLaurin; Stuart L Solomon; John S Douglas; Michael W Ball; Ronald P Caputo; Ash Jain; Thaddeus R Tolleson; Bernard M Reen; Ajay J Kirtane; Peter J Fitzgerald; Kweli Thompson; David E Kandzari Journal: J Am Coll Cardiol Date: 2010-02-09 Impact factor: 24.094
Authors: David E Kandzari; Pieter C Smits; Michael P Love; Ori Ben-Yehuda; Shmuel Banai; Simon D Robinson; Michael Jonas; Ran Kornowski; Rodrigo Bagur; Andres Iniguez; Haim Danenberg; Robert Feldman; Rajiv Jauhar; Harish Chandna; Manish Parikh; Gidon Y Perlman; Mercedes Balcells; Peter Markham; Melek Ozgu Ozan; Philippe Genereux; Elazer R Edelman; Martin B Leon; Gregg W Stone Journal: Circulation Date: 2017-08-09 Impact factor: 29.690
Authors: Ajay J Kirtane; Martin B Leon; Michael W Ball; Harpaul S Bajwa; Michael H Sketch; Patrick S Coleman; Robert C Stoler; Stylianos Papadakos; Donald E Cutlip; Laura Mauri; David E Kandzari Journal: JACC Cardiovasc Interv Date: 2013-03-20 Impact factor: 11.195
Authors: Angelo Mastrangelo; Giovanni Monizzi; Stefano Galli; Luca Grancini; Cristina Ferrari; Paolo Olivares; Mattia Chiesa; Giuseppe Calligaris; Franco Fabbiocchi; Piero Montorsi; Antonio L Bartorelli Journal: Front Cardiovasc Med Date: 2022-02-21
Authors: Gal Sella; Gera Gandelman; Nicholay Teodorovich; Ortal Tuvali; Omar Ayyad; Haitham Abu Khadija; Dan Haberman; Lion Poles; Michael Jonas; Igor Volodarsky; Jacob George; Alex Blatt Journal: J Clin Med Date: 2022-03-27 Impact factor: 4.241
Authors: Michael D Dake; Fabrizio Fanelli; Aaron E Lottes; Erin E O'Leary; Heidi Reichert; Xiaohui Jiang; Weiguo Fu; Osamu Iida; Kan Zen; Marc Schermerhorn; Thomas Zeller; Gary M Ansel Journal: Cardiovasc Intervent Radiol Date: 2020-10-06 Impact factor: 2.740